Agreement Termination By Counterparty, Contractual Time Threshold

No definition available.

Name:	nbix_AgreementTerminationByCounterpartyContractualTimeThreshold
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination By Counterparty, Minimal Contractual Time

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationByCounterpartyMinimalContractualTime
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination, Contractual Time Threshold

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationContractualTimeThreshold
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination, Minimal Contractual Time

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationMinimalContractualTime
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Board Of Directors Maximum Duration Term

+ References

No definition available.

+ Details

Name:	nbix_BoardOfDirectorsMaximumDurationTerm
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments made for milestones under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_MilestonePayment
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number Of Development Candidate

+ References

No definition available.

+ Details

Name:	nbix_NumberOfDevelopmentCandidate
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Gene Therapy Programs

+ References

No definition available.

+ Details

Name:	nbix_NumberOfGeneTherapyPrograms
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Non-clinical Stage Compound

+ References

No definition available.

+ Details

Name:	nbix_NumberOfNonClinicalStageCompound
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Preclinical Candidates

+ References

No definition available.

+ Details

Name:	nbix_NumberOfPreclinicalCandidates
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Undisclosed Programs

+ References

No definition available.

+ Details

Name:	nbix_NumberOfUndisclosedPrograms
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	nbix_PatentTerm
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential later stage milestone payments and royalties.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePaymentReceipts
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of potential milestone payments to be paid under a license agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePayments
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Milestone Royalties At Tiered Percentage

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestoneRoyaltiesAtTieredPercentage
Namespace Prefix:	nbix_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of shares sold by the collaboration partner per stock transaction.

+ References

No definition available.

+ Details

Name:	nbix_SaleOfStockNumberOfSharesSoldInTransaction
Namespace Prefix:	nbix_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payments made under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_UpfrontPaymentsMade
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

+ Details

Name:	us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_EquitySecuritiesFvNiCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period remaining for contractual sale restriction on equity security measured at fair value with change in fair value recognized in net income (FV-NI), subject to contractual sale restriction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes investment in equity security by investment company for which discount for contractual sale restriction is applied.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B

+ Details

Name:	us-gaap_EquitySecurityFvNiContractualSaleRestrictionRemainingPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_NxeraPharmaUKLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_A2019VoyagerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_A2023VoyagerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_SanofiS.AMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_AbbVieIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) undisclosedProgram geneTherapyProgram candidate non-clinicalStageCompound preclinicalCandidate	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	Jun. 30, 2025 USD ($)	Jan. 31, 2025 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development		$ 12.5	$ 143.9	$ 0.0
Revenues		2,355.3	1,887.1	1,488.7
Collaborative Arrangement \| Common Stock \| Voyager
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership	19.90%
Collaborative Arrangement \| Nxera Pharma UK Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		50.0		30.0
Potential milestone payments		$ 2,500.0
Agreement termination, minimal contractual time		180 days
Agreement termination, contractual time threshold		90 days
Agreement termination by counterparty, contractual time threshold		365 days
Agreement termination by counterparty, minimal contractual time		120 days
Collaborative Arrangement \| Nxera Pharma UK Limited \| Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments						$ 15.0
Collaborative Arrangement \| Takeda
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 7.5		5.0
Potential milestone payments		$ 1,900.0
Agreement termination, minimal contractual time		6 months
Agreement termination, contractual time threshold		12 months
Number of non-clinical stage compounds \| non-clinicalStageCompound		3
Collaborative Arrangement \| Takeda \| Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments							$ 35.0
Collaborative Arrangement \| Xenon
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development				7.3
Potential milestone payments		$ 1,700.0
Agreement termination, contractual time threshold		90 days
Number of preclinical candidates \| preclinicalCandidate		3
Milestone payment				$ 15.0
Share price (in USD per share) \| $ / shares				$ 31.855
Equity securities purchase date fair value amount				$ 7.7
Collaborative Arrangement \| Xenon \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares				0.3
Collaborative Arrangement \| Voyager \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period for voting restrictions	3 years
Collaborative Arrangement \| 2019 Voyager Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 5.0
Potential milestone payments		$ 1,300.0
Agreement termination, minimal contractual time		180 days
Agreement termination, contractual time threshold		1 year
Share price (in USD per share) \| $ / shares					$ 11.9625
Equity securities purchase date fair value amount					$ 54.7
Number of undisclosed programs \| undisclosedProgram		2
Collaborative Arrangement \| 2019 Voyager Agreement \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares					4.2
Collaborative Arrangement \| 2023 Voyager Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 6.0
Potential milestone payments		$ 6,100.0
Agreement termination, minimal contractual time		180 days
Agreement termination, contractual time threshold		1 year
Share price (in USD per share) \| $ / shares	$ 8.88
Number of gene therapy programs \| geneTherapyProgram		3
Upfront payments made	$ 175.0
Board of directors maximum duration term	10 years
Equity securities cost	$ 31.3
Acquired in-process research and development	$ 143.9
Number of development candidate \| candidate		2
Collaborative Arrangement \| 2023 Voyager Agreement \| Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares	4.4
Collaborative Arrangement \| Sanofi S.A
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 5.0
Potential milestone payments		$ 10.0
Collaborative Arrangement \| Sanofi S.A \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties at tiered percentage		3.00%
Collaborative Arrangement \| Sanofi S.A \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties at tiered percentage		5.00%
Collaborative Arrangement \| Sanofi S.A \| Patents \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Patent term		16 years
Collaborative Arrangement \| MTPC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement termination, contractual time threshold		180 days
Revenues				$ 20.0
Potential milestone payment receipts		$ 30.0
Collaborative Arrangement \| MTPC \| Patents \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Patent term		10 years
Collaborative Arrangement \| AbbVie Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement termination, contractual time threshold		180 days
Potential milestone payment receipts		$ 366.0
Collaborative Arrangement \| AbbVie Inc. \| Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 13.5	$ 16.7	$ 21.2
Collaborative Arrangement \| AbbVie Inc. \| Patents \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Patent term		10 years